AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04114981 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT02679690 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standard Dietary Sodium Education
Description: Standard dietary education for sodium restricted diets for patients with heart failure.
Study NCT02679690 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Color-Coded Cue Cards
Description: The use of a color-coded cue card to designate ranges of acceptable sodium content of food for comparison to labels while grocery shopping.
Study NCT04499248 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AGN-193408 SR
Description: An implant containing preservative-free AGN-193408 dispersed in a biodegradable polymer matrix. Implants are preloaded into an applicator to facilitate insertion of the implant into the anterior chamber of the study eye.
Study NCT04499248 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lumigan
Description: Control Treatment in Fellow Eye Lumigan 0.01% is a topical eye drop that is a solution containing 0.1 mg/mL bimatoprost
Study NCT02163811 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: VETPALS
Description: VETPALS is an adaption of an empirically supported self-management program, PALS (Promoting Amputee Life Skills). The PALS program demonstrated improved physical and psychosocial functioning when delivered in community-based support groups for amputees, but this program has not been adapted for the needs of Veterans and implemented in the VA healthcare system.~VETPALS is a five session course for people with life changes after amputation. The five sessions are held weekly, and are facilitated by a VA clinician in conjunction with a peer facilitator (Veteran with limb loss). Veterans receive all usual care.
Study NCT02163811 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Individual Education Support Program
Description: VETPALS facilitator provide post-amputation education materials from the Amputee Coalition, including First Step - A Guide for Adapting to Limb Loss and Side Step - A Guide to Preventing and Managing Diabetes and Its Complications. Veterans receive all usual care.
Study NCT04499248 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sham Administration
Description: Needleless applicator contacting similar intracameral insertion location on eye as AGN-193408 SR.
Study NCT04499248 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lumigan Vehicle
Description: Vehicle eye drops (for masking) will be administered once daily in the evening starting on Day 1 in the study eye during Cohort 2.
Study NCT00425659 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: home sleep study
Description: different in algorithm arrangement for diagnosing sleep apnea
Study NCT00425659 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: home CPAP titration (Autoset)
Description: continuous positive airway pressure device for treatment of sleep apnea
Study NCT00425659 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: CPAP
Description: usual practice
Study NCT01787214 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Full dose
Description: 20% of daily energy needs supplied by walnuts
Study NCT01787214 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Half dose
Description: 10% of daily energy needs supplied by walnuts
Study NCT01787214 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Control
Description: Walnut free meals
Study NCT04499248 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AGN-193408 SR
Description: An implant containing preservative-free AGN-193408 dispersed in a biodegradable polymer matrix. Implants are preloaded into an applicator to facilitate insertion of the implant in the study eye.
Study NCT04499248 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sham Administration
Description: Needleless applicator contacting similar insertion location on eye as AGN-193408 SR.
Study NCT04499248 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lumigan Vehicle
Description: Vehicle eye drops (for masking) will be administered once daily in the evening starting on Day 1 in the study eye during Cohort 3.
Study NCT02098356 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low Bicarbonate
Description: Low bicarbonate hemodialysis - 30 mEq/L dialysate bicarbonate
Study NCT00948402 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: metformin 1250 mg three times daily
Study NCT00948402 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: oral contraceptive
Description: 30 µg ethinylestradiol plus 30 mg drospirenone 21 day/month.
Study NCT02711150 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PLL Length Measured through US
Description: The PLL will be measured for each allocated position: EPD or Flexed Position
Study NCT02711150 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: PLL Length Measured through US
Description: The PLL will be measured for each allocated position: EPD or Flexed Position
Study NCT03943173 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy
Description: Given standard chemotherapy
Study NCT03943173 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib
Description: Given PO
Study NCT03943173 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Therapeutic Conventional Surgery
Description: Undergo surgery
Study NCT04121000 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: VIDEO ASSISTED THOTACOSOPIC SURGERY
Description: VATS
Study NCT02357550 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ketone
Description: 3-OHB is infused intravenously.
Study NCT02357550 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Saline infusion.
Study NCT01073020 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Allergan Adjustable Gastric Band Surgery
Study NCT01073020 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Intensive Medical Diabetes & Weight Management (Why WAIT) - Band Group
Description: Intensive Medical Diabetes \& Weight Management (Why WAIT) - Band Group
Study NCT01073020 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Roux-en-Y Gastric Bypass (RYGB) Surgery
Study NCT01073020 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Intensive Medical Diabetes & Weight Management (Why WAIT) - Bypass Group
Description: Intensive Medical Diabetes \& Weight Management (Why WAIT) - Bypass Group
Study NCT00003533 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antineoplaston therapy (Atengenal + Astugenal)
Description: Patients with Metastatic Pancreatic Cancer will receive Antineoplaston therapy (Atengenal + Astugenal).~The daily doses of A10 and AS2-1 are divided into six infusions, which are given at 4-hourly intervals. Each infusion starts with infusion of A10 and is immediately followed by infusion of AS2-1.
Study NCT02878291 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Meningococcal ACYW135 Polysaccharide Conjugate Vaccine
Description: Group 1:3/2/1 dose(s) according to age of subjects. Single intramuscular dose contains 10 µg each of Serogroup A, C, Y, and W135 polysaccharide conjugated to Tetanus Toxoids.
Study NCT02878291 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Meningococcal ACYW135 Polysaccharide Conjugate Vaccine
Description: Group 2:3/2/1 dose(s) according to age of subjects. Single intramuscular dose contains 5 µg each of Serogroup A, C, Y, and W135 polysaccharide conjugated to Tetanus Toxoids.
Study NCT03910803 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Brodalumab
Description: Brodalumab is a human monoclonal IgG2κ antibody directed against human interleukin-17 receptor A (IL-17RA). It is expressed in a Chinese Hamster Ovary (CHO) cell line. Brodalumab is comprised of 1312 amino acids and has an estimated molecular mass of 144,000 Daltons.~Brodalumab Injection is a sterile, preservative-free, yellow solution, delivered via subcutaneous injection. . Each Brodalumab single dose prefilled syringe delivers 1.5 mL of solution containing 210 mg of brodalumab formulated in glutamate (6.5 mg), polysorbate 20 (0.15 mg), proline (36 mg), and Water for Injection, USP at pH 4.8.
Study NCT00882167 — intervention group
Intervention type: OTHER
Intervention: CineMRI
Description: CineMRI scan of the abdomen at 1.5 Tesla.
Study NCT00313053 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Human mAb 216
Description: Two treatment courses of mAb infusion will be given, with the same dose of antibody administered on Day 0 and on Day 7.
Study NCT00313053 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine
Description: Vincristine 1.5 mg/m2/dose (max dose = 2 mg) IVP on weekly x 4 doses (Days 7, 14, 21, 28)
Study NCT03932084 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Control group
Description: During hospitalization:~1. Monitor subjects' blood glucose;~2. One-on-one education: Education includes skills related to diabetes self-management, basic knowledge of diabetes, diet, exercise, medication, blood glucose monitoring, risks of glucose fluctuations;~3. Teaching patients and their families to use blood glucose meters and correctly record results. The diabetes specialist nurses demonstrate correct methods for self-monitoring blood glucose.~During discharge: Patients were given standard hospital discharge instructions and were asked to monitor their blood glucose 5 times daily after discharge.~Follow-up: If a patient FPG was less than 7 mmol/L, 2hPG was less than 10 mmol/L, or A1c was less than 7%, no intervention would be implemented. If one of these items was above the numbers, a referral would be made to an endocrinologist for medication adjustment. Participants received telephone follow-up one week after discharge, thereafter, follow-up were conducted once a month.
Study NCT03932084 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Glucose fluctuation targeted intervention
Description: We set achieving goals for this intervention group (both A1c\<7% and LAGE\<80mg/dl). Participants received the same usual care as the control group; though additional attention was paid to glucose fluctuation on the basis of glucose control. Even the patient's FPG, 2hPG, and A1c were all well controlled, If his or her LAGE≥80mg/dl, we would carefully assess the patient's diet and exercise and daily activities first. If it was caused by lifestyle or events, the researchers worked with patients to find a self-care behavioral solution for the glucose fluctuation, and set behavioral goals, otherwise, the researchers would refer the patient to an endocrinologist for medication adjustment. During next follow-up, we evaluated the glucose fluctuation and target completion.
Study NCT02505776 — intervention group
Intervention type: DRUG
Intervention: Bimatoprost cutaneous solution 0.03%
Description: Bimatoprost cutaneous solution 0.03% (GLASH VISTA™) prescribed as per standard of care in clinical practice.
Study NCT05138198 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mediterranean Diet & Physical Activity
Description: At the beginning of each week (1-10), members were sent a text message introducing the week and providing the link to the week's website. This website includes downloadable material for this group with recipes and other important nutrition information, as well as the weekly topic information and informative video. After receiving the link to the website, members received a Qualtrics survey with a teach-back question related to the video and a goal-setting question related to the topics of the week. At the end of each week, members received another Qualtrics survey with a question regarding the goal of the past week.~* Visit 1: discuss Mediterranean diet score results from baseline and ways to improve~* Visit 2: discuss anti-inflammatory diet scorecard and ways to improve~* Discuss optimal dietary pattern (Med Diet pyramid handout)~* Personal dietary and exercise goals, reviewed baseline intake form, social support, self-efficacy, challenges, or barriers to achieving goals
Study NCT05138198 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: As part of usual care, members attended one-on-one monthly counseling sessions with the assigned dietitian and reviewed their current eating habits and physical activity, as well as other environmental factors that may be affecting their weight such as work, home environment, sleeping issues, and medications. After reviewing current practices, the RD provided medical nutrition therapy (MNT), a specific application of the Nutrition Care Process in clinical settings that focuses on the management of diseases (e.g. diabetes, heart disease, etc.). Specific dietary recommendations are based on the Bull's Eye Food Guide, used by Stony Brook University Hospital for outpatient nutrition counseling. Individuals in the standard care received more individualized calorie recommendations (usual care) than the Mediterranean diet group.
Study NCT04248374 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Taste Intensity
Description: Taste intensity with and without sour adaptation
Study NCT04670757 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CPL409116
Description: IMP administration, tablets contain CPL409116 as an active ingredient
Study NCT04670757 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo comparator
Study NCT03246568 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Renal Nerve Denervation
Description: Bilateral renal denervation using a multi-polar radiofrequency ablation catheter (Symplicity™ Spyral Cather, Medtronic) in the right and left main, branch, and accessory renal arteries in vessels ranging in diameter between 3 and 8 mm.
Study NCT03246568 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Pulmonary vein isolation
Description: PVI by cryo-balloon ablation without linear ablation
Study NCT03246568 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pulmonary vein isolation
Description: PVI by cryo-balloon ablation without linear ablation
Study NCT04638855 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Medicurtain®
Description: Anti-adhesion barrier (Medicurtain® 5ml prefilled syringe after hysteroscopy surgery)
Study NCT04638855 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Placebo
Description: No device after hysteroscopy surgery
Study NCT03799978 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACT-541468
Description: ACT-541468 50 mg film-coated tablets
Study NCT03320343 — intervention group
Intervention type: OTHER
Intervention: MRI
Description: 3D morphological MRI and diffusion tensor imaging
Study NCT02580578 — intervention group
Intervention type: OTHER
Intervention: No Intervention
Description: No intervention is administered in this study.
Study NCT01306461 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Timolol and Tafluprost
Description: Preservative-free Timolol eye drops administered twice daily concomitantly with preservative-free Tafluprost eye drops administered once daily~Treatment period 6 months
Study NCT01306461 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fixed Dose Combination of tafluprost and timolol
Description: Preservative-free Fixed Dose Combination of tafluprost and timolol eye drops administered once daily.~For masking purposes also: vehicle for timolol administered twice daily~Treatment period 6 months
Study NCT01620489 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: liraglutide
Description: 1.8 mg administered once daily subcutaneously (s.c., under the skin) as add-on to the subject's stable pre-trial oral antidiabetic drug (OAD) and/or insulin regimen.
Study NCT01620489 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Administered once daily subcutaneously (s.c., under the skin) as add-on to the subject's stable pre-trial oral antidiabetic drug (OAD) and/or insulin regimen.
Study NCT02314520 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: peripherally inserted central catheter
Description: Any complication associated with central access
Study NCT02314520 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: centrally inserted central catheter
Description: Central access not associated with any complication
Study NCT00647166 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: corticosteroid and azathioprine
Description: * Corticosteroid 1 mg/kg/day with a conventional decrease dose~* Azathioprine : 2 mg/kg/day during one year in 2 to 3 times a day by oral route
Study NCT01690871 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BEZ235
Description: Patients will be provided with an adequate supply of study treatment for self-administration at home. Unless otherwise warranted, new study drug packages will be provided to the patient at Cycle 1 Day 1 (start of treatment) and at Day 1 of each following treatment cycle. The first dose of BEZ235 (Cycle1 Day1) must be taken at the hospital.
Study NCT00930644 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: teduglutide
Description: 0.05 mg/kg/day subcutaneously taken once per day for 24 months
Study NCT04096261 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Diagnostic Test
Description: Diagnostic Test: Contrast agentenhanced MRI using Gadovist by using the contrast agent Gadovist we aim to visualize the blood-brain barrier. Furthermore, we aim to measure a newly developed biomarker of the blood-brain barrier in the cerebro-spinal fluid. And sleep quality measurement with a polysomnography.
Study NCT00647166 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: corticosteroid and placebo
Description: * Corticosteroid 1 mg/kg/day with a conventional decrease dose~* Placebo : 2 mg/kg/day during one year in 2 to 3 times a day by oral route
Study NCT02257632 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ranibizumab 0.5 mg
Description: Administered as an intravitreal injection
Study NCT02257632 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aflibercept 2 mg
Description: Administered as an intravitreal injection
Study NCT01325519 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: video decision aid
Description: video
Study NCT02650388 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Cognitive fuction, quality of life
Description: To test the above score in patients undergoing TAVI
Study NCT04494503 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: APG-2575
Description: APG-2575 orally once daily, every 28 days as a cycle.
Study NCT04194905 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levonorgestrel 0.1 mg and Ethinyl estradiol 0.02 mg Test Product
Description: Coated Tablets
Study NCT04194905 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levonorgestrel 0.1 mg and Ethinyl estradiol 0.02 mg Reference Product
Description: Coated Tablets
Study NCT03810833 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Brilliance device sensor
Description: Two separate sensors will be attached via standard, single-use adhesive pads to the left and right pectoralis major on each participant.
Study NCT04378010 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EDP-305 1.5 mg
Description: Tablet
Study NCT04378010 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EDP-305 2 mg
Description: Tablet
Study NCT04494503 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Rituximab 375mg/m2 ivgtt on C1D8 and 500mg/m2 ivgtt on C2-6D1.
Study NCT04494503 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibrutinib
Description: Ibrutinib 420mg orally once daily during C1D8-28 and following cycles.
Study NCT02857816 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: NURO System PTNM Therapy
Study NCT04378010 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Tablet
Study NCT01873846 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Silicone Hydrogel Contact Lens
Study NCT01889329 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: RUTF-1
Description: Made from local food ingredients
Study NCT01889329 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: RUTF-2
Description: Made from local food ingredients
Study NCT01889329 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Plumpynut
Description: Commercially made from peanut paste
Study NCT03563599 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Telacebec (Q203)
Description: High, Mid, Low dose of telacebec
Study NCT03563599 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rifafour e-275
Description: RHZE (R=rifampicin: H=isoniazid: Z=pyrazinamide: E=ethambutol)
Study NCT04227431 — intervention group
Intervention type: OTHER
Intervention: Insulin degludec
Description: Participants have been treated with Tresiba® (insulin degludec) for at least 20 weeks before entering the study. The study will be based on data already recorded in participants' medical records for approximately the last year and no new tests or procedures are required as part of the study.
Study NCT01070368 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Commercial extract and in-house wheat extract
Description: Patients with a history of wheat allergy underwent two skin test extracts, and open challenge with wheat. A blood test for specific IgE was performed in the same time.